Blood Flow Bypass Catheters and Methods for the Delivery of Medium to the Vasculature and Body Ducts

ABSTRACT

A catheterization device that may be designed by use of an adaptive genetic algorithm computational fluid dynamics approach, as well as other Global Optimization methods that may include simulated annealing, multistart and interval methods, con-tinuous branch and bound methods, evolutionary algorithms, and tabu search and scatter search methods, as well as other available Global Optimization methods that is able to maximize/optimize the dwell time of an infused agent in the vicinity of a vascular lesion. The device may have an internal by-pass channel that allows the blood upstream of the lesion to continue its pulsatile flow through the vessel in the part of it occluded by the lesion, while simultaneously allowing the disbursement and maximal dwell time of an antithrombolytic or other diagnostic or therapeutic agent needed to treat the lesion. Different embodiments of the catheterization device are disclosed and indications for the use of these devices in the treatment of vascular diseases are discussed.

CROSS-REFERENCES TO RELATED APPLICATIONS

The present application claims priority from U.S. Provisional PatentApplication Ser. 60/653,397, filed on Feb. 16, 2005, entitled “BloodFlow Bypass Catheter for the Delivery of Agents to Lesions in thePeripheral Vasculature,” the disclosure of which is hereby incorporatedby reference herein in its entirety.

FIELD OF THE INVENTION

The invention relates to the field of catheterization devices andmethods for delivering a medication or the like to a lesion in avascular structure or duct of a patient, as well as a method of forgenerating configuration catheterization device designs for optimizingperformance.

BACKGROUND OF THE INVENTION

The need for developing ever more efficacious methods of treatingperipheral vascular disease (PVD) which, like coronary artery disease(CAD), is the progressive narrowing of the arterial tree by theatherosclerotic process. These diseases result in diminished blood flowto vital organs and extremities beyond the site of narrowing orocclusion. Diabetes mellitus (DM) is a major contributor to such diseaseprocesses, as are a large number of other well-known health risks andfactors, such as elevated levels of cholesterol. As the prevalence ofthese factors increases, so does that of PVD and CAD. For example, PVDaffects an estimated 27 million people in Europe and North America, andit produces significant morbidity and mortality in those populations. Anestimated 10.5 million of those affected are symptomatic while 16.5million are asymptomatic. Despite the prevalence of PVD, it is estimatedthat only 25% of symptomatic patients are currently treated for thedisease.

PVD typically affects multiple segments of a given artery. Shortsegments of severe narrowing are typically treated with catheter-basedtechniques such as angioplasty and the placement of one or more stents.When there is severe narrowing over a long segment or involving multiplearteries within a limb, surgical revascularization is the treatment ofchoice. When this is insufficient, particularly in the diabeticpopulation, limb amputation is indicated, and an estimated 60,000 areperformed annually in the United States. Severe narrowing within thevessel or related causes of poor blood flow commonly result in theformation of intra-arterial thrombus (clot) formation, which, if notimmediately corrected, will lead to the death of tissue and the need foramputation of the host limb. Endovascular catheter placement for thedelivery of a thrombolytic agent to dissolve the clot is efficacious,but commonly requires days of drug infusion, intensive care monitoring,and frequent trips to a radiology suite to reposition the catheter.

Systemic administration of therapeutic agents allows for wide-spreaddistribution of these agents throughout the body. The function of thetherapeutic agent depends upon the uptake of the medication by thetargeted organ and upon the agent's pharmacokinetics which determine itsconcentration as a function of time. However, with systemic delivery,non-targeted organs may be adversely affected by the medication, andthis can cause potentially serious side-effects. Consequently, theefficacy of the therapeutic agents at the target site can be limited byboth its concentration at the site of interest and by its toxicity inother non-targeted organs.

The clinical benefits of site-specific catheter-based delivery systemsfor the administration of therapeutics can include increased safety,increased efficacy, reduced toxicities, more reliable therapeutic druglevels, and decreased and simplified dosing requirements. Safety,efficacy and toxicity are all independent but related parameters in thepharmacokinetics of each therapeutic agent. Site-specific drug deliveryinto the target tissue ensures that the majority of the drug goes to thesite it is intended to act upon with minimal or at least small andtolerable effect upon non-targeted tissue, thereby decreasing theeffects of toxicity. This allows for higher concentrations of thetherapeutic agent to be administered to the targeted site, therebyincreasing the efficacy of the agent. An additional benefit ofsite-specific delivery of therapeutic agents is that the patientreceives a smaller cumulative dose, thereby further reducing the overallrisk to the patient.

Site-specific catheter-based drug delivery allows local administrationof therapeutic agents and reliable therapeutic drug levels to beachieved and maintained because systemic clearance is reduced. Byobtaining reliable therapeutic drug levels in this manner, dosingrequirements are decreased and simplified. As mentioned above, localdrug levels can be maintained at higher levels than could be achievedwith systemic administration because systemic toxicity is reduced withlocal delivery.

A site-specific drug-delivery catheter is also required when activebiologic agents are being administered to a focal site of injury. As anexample, site-specific delivery of thrombolytic therapy to the site of aclot in the vascular tree of an ischemic limb is preferred to systemicdelivery. With site-specific delivery, a high local concentration of thethrombolytic agent can be delivered to achieve lysis of the clotmaterial at the site of infusion, whereas, systemic delivery of athrombolytic therapy could lead to generalized bleeding at multipleremote sites.

An emerging modality for the treatment of PVD is site-specific stem celltherapy for the treatment of ischemic limbs. This cellular therapy hasdemonstrated efficacy in the formation of new blood vessels in ischemiclimbs of patients with PVD in a recently published randomized controlledclinical study. The increasing population of patients with DM and PVDpotentially makes this a very large market.

One alternative that can obviate the problem of washout of thethrombolytic agent downstream from the lesion is to occlude the arterywith a blockage means such as a balloon placed distally from the lesionbeing treated. While effective over brief periods intra-operatively,this approach does limit the time over which the agent can act, becausedownstream arterial occlusion cannot be maintained indefinitely withoutischemic injury to dependent tissues and organs. These problems arisenot only with the catheter-based delivery of thrombolytics, but alsowhen delivering new and emerging classes of agents such as stem cellsuspensions and angiogenesis factors.

These clinical needs have driven many substantial efforts aimed atcatheter development over the past several years, and a variety ofdevices has been designed as a result. Generally speaking, the mostinteresting class of devices is that which incorporates internalchannels or create pathways that allow blood flow past the lesion whiledrugs or other therapies are being delivered to the lesion eitherthrough a balloon that is integral to the catheter or from portselsewhere on it. Integral balloons can also be used to carry outangioplasty on the lesion or to temporarily block the artery during drugdelivery to the lesion. Within the medical device community, suchcatheters are often referred to as perfusion sleeves, and there is alarge literature on the topic. For a succinct overview of the spectrumof catheters that includes some of these devices see Yang (Yang X:Imaging of Vascular Gene Therapy. Radiol. 228:36-49, 2003, of which ishereby incorporated by reference herein in its entirety) who listsseveral of the commercially available systems now being employed for theimage-based delivery of intravascular gene therapies.

A frequent use of perfusion sleeve devices is within the context ofpercutaneous transluminal angioplasty, although applications for them ina variety of other interventions have been conceived, clinically tested,and put into routine use as well. An early multiple-cuff catheter withwindows on the shaft to shunt the arterial blood flow past the treatmentzone was described by Baran et al. (Baran O E, Baran A O D: MultipleSurgical Cuff. U.S. Pat. No. 4,423,725, 1984, of which is herebyincorporated by reference herein in its entirety). Others are those ofSchweich et al. (Schweich Jr. C J, Harrison K D, Burns M M: BloodPerfusion Catheter. U.S. Pat. No. 5,716,340, 1998, of which is herebyincorporated by reference herein in its entirety), who introduced aperfusion-shunt channel via an inflatable balloon wound toroidallyaround the catheter shaft, and Macoviak et al. (Macoviak J A, Samson WJ, Leary J J, Esch B D: Perfusion Shunt Apparatus and Method. U.S. Pat.No. 6,139,517, 2000, of which is hereby incorporated by reference hereinin its entirety), who developed a stand-alone shunt apparatus that couldbe mounted on a catheter for use in the aortic arch. Lary (Lary B G:Passive Perfusion Sleeve/Placement Catheter Assembly. U.S. Pat. No.6,506,180, 2003, of which is hereby incorporated by reference herein inits entirety) incorporated a specially designed inflation lumen for theperfusion sleeve's angioplasty balloon.

Several types of perfusion sleeve devices have also been designed fordrug delivery simultaneous with balloon angioplasty. One such catheterdescribed in the literature for this purpose was the “infusion sleeve”system of Moura et al. (Moura A, Jules Y T, Lam M D, Hébert D, Kermode JR, Grant G W, Robitaille D, Klein E J, Yock P G, Simpson J B, Kaplan AV: Intramural Delivery of Agent via a Novel Drug-Delivery Sleeve.Circulation 92:2299-2305, 1995, of which is hereby incorporated byreference herein in its entirety), which was used for applications suchas the delivery of heparin to lesions on the arterial wall (Kaplan A V,Vandormael M, Hofman M, Weil H J, Störger H, Krajcar M, Gallant P,Simpson J B, Reifart N: Heparin Delivery at the Site of Angioplasty witha Novel Drug Delivery Sleeve. Am. J. Cardiol. 77:307-310, 1996, of whichis hereby incorporated by reference herein in its entirety). A variantof it that was optimized specifically for perfusion capabilities wasintroduced in 1998 (Cannan C R, Kaplan V A, Klein E J, Galant P, SharafB L, Williams D O: Novel Perfusion Sleeve for Use During BalloonAngioplasty: Initial Clinical Experience. Catheteriz Cardiovasc. Diag.44:358-362, 1998, of which is hereby incorporated by reference herein inits entirety) and subsequently used in angioplasty procedures. Examplesof some other more recent flow bypass devices include those described byEvans et al. (Evans M A, Demarais D M, Eversull C S, Leeflang S A:System and Methods for Clot Dissolution. U.S. Pat. No. 6,663,613, 2003,of which is hereby incorporated by reference herein in its entirety) andZadno-Azizi et al. (Zadno-Azizi G R, Patel M R, Muni K P, Bagaosian C J,Ha H V: Method for Containing and Removing Occlusions in the CarotidArteries. U.S. Pat. No. 6,90,204, 2004, of which is hereby incorporatedby reference herein in its entirety).

A general and consistent limitation of the prior art is that, amongother things, the bulk of the design work on this class of catheters hasbeen done without detailed assessment of the flows by reference toComputational Fluid Dynamics (CFD) or to experiments performed on scaledup physical platforms that retain geometrical and dynamical similaritywith the catheters. Instead, much of the modeling has been far moreempirical in nature, relying typically on observations with prototypedevices, and with the design iterations then made largely on the basisof those results. This is a perfectly valid approach and has been used,for example, to investigate side-slit versus side-hole geometries fordrug delivery ports on intravascular pulse-spray catheters (Cho K J,Recinella D K: Pattern of Dispersion from a Pulse-Spray Catheter forDelivery of Thrombolytic Agents. Acad. Radiol. 4:210-216, 1997, of whichis hereby incorporated by reference herein in its entirety). On theother hand, the total cross-sectional area of a 3 mm inner-diameterartery is only 7 mm², thus restricting the catheter cross section toperhaps 5 mm² or less, for such an artery. Therefore, the real estateavailable for a balloon inflation lumen, a drug delivery lumen, aperfusion bypass lumen, a guidewire channel, etc. is very limited. As aresult, biomedical engineers have often had to introduce complexmulti-purpose channels into their catheter designs in order tocircumvent this limitation.

SUMMARY OF THE INVENTION

To overcome this general limitation, we set forth herein a designprocess for perfusion sleeve catheters based on, among other things, thecombination of adaptively guided computational fluid dynamics (CFD)modeling and scaled up experiments of the flows and species masstransport involved that can provide useful quantitative guidance on thegeometry and relative placement of port holes, internal lumens and otherstructural features of the catheter that critically impact itsperformance. In particular, we provide an adaptive design process basedon a Genetic Algorithm-guided CFD approach (or other globaloptimization-guided approaches; as well as any other suitable andavailable approaches/algorithms) that leads to non-intuitively designedcatheters that allow for indefinitely long dwell time of a thrombolyticagent (or other optimizations of concentration levels and time) in thevicinity of a lesion while maximizing the blood flow (or otheroptimizations of concentration levels and time) bypassed around thelesion.

Therefore, according to various embodiments of the present invention,catheter designs are provided for which the blood flow through theregion of the lesion can continue uninterrupted while the medication isbeing simultaneously applied to the lesion such that the treatmentconcentration levels and time are optimized.

Further, methods (e.g., techniques and algorithms) for positioning andutilizing the catheter are provided for optimizing the concentration anddwell time of the medication being applied to the lesion.

An aspect of various embodiments of the present invention provides acatheter device for insertion into a vascular structure or body duct,wherein the catheter device is designed by employment of a globaloptimization algorithm based computational fluid dynamics approach. Thecatheter device having a distal end and a proximal end for delivery of amedium to a lesion. The device comprising: a blood lumen for allowingblood to pass there through; a medium lumen for the delivery of a mediumto the lesion, the medium lumen comprising at least one medium egressport for communication with the lesion; an expandable component disposedon the catheter device to block or impede the vascular flow of blood inthe vascular structure or body duct; and the blood lumen comprising atleast one blood entrance port proximally before the expandable componentto allow blood to enter and at least one blood egress port distallybeyond the expandable component to allow blood to pass distally beyondthe expandable component. The global optimization algorithm may comprisea genetic algorithm/method. The global optimization algorithm maycomprise at least one of simulated annealing, multistart and intervalmethods, continuous branch and bound methods, evolutionary algorithms,and tabu search and scatter search methods, as well as other availableGlobal Optimization methods. Furthermore, any other suitable andavailable approach/algorithm may be implemented as well.

An aspect of various embodiments of the present invention provides for amethod for delivering a medium to a lesion inside of a vascularstructure or body duct by inserting a catheter device designed by aglobal optimization algorithm based computational fluid dynamicsapproach into a subject. The catheter device having a distal end and aproximal end, lumens there through, medium port holes, and blood portholes. The method comprises: inflating an expandable component to blockor impede the vascular flow of blood or other body fluid through thevasculature structure or the body duct; delivering the medium throughone of the lumens to the lesion through at least one of the medium portholes; and allowing blood of the vasculature of the subject toproximally enter through at least one of the blood port holes and flowthrough one of the lumens and to exit on a side of the lesion toward thedistal end of the catheter device through at least one of the blood portholes. The global optimization algorithm may comprise a geneticalgorithm/method. The global optimization algorithm may comprise atleast one of simulated annealing, multistart and interval methods,continuous branch and bound methods, evolutionary algorithms, and tabusearch and scatter search methods, as well as other available GlobalOptimization methods. Furthermore, any other suitable and availableapproach/algorithm may be implemented as well.

An aspect of various embodiments of the present invention provides for amethod for generating a configuration of elements of a catheter devicefor use inside a vasculature or body duct of a subject that includesinserting the catheter device into the subject. The catheter devicecomprising passages for blood flow and medium flow and inlet and exitports for blood flow and medium flow. The method comprising: selectingvariables including at least one of: a) geometrical shapes anddimensions of at least some of the blood passages and the mediumpassages, and b) relative locations and orientations of flow planes ofat least some of the inlet ports and exit ports; and applying a globaloptimization algorithm to the variables to generate a catheter withoptimized flow conditions. The global optimization algorithm maycomprise a genetic algorithm/method. The global optimization algorithmmay comprise at least one of simulated annealing, multistart andinterval methods, continuous branch and bound methods, evolutionaryalgorithms, and tabu search and scatter search methods, as well as otheravailable Global Optimization methods. Furthermore, any other suitableand available approach/algorithm may be implemented as well.

An aspect of various embodiments of the present invention provides for acomputer program product comprising a computer useable medium havingcomputer program logic for enabling at least one processor in a computersystem to generate a configuration of elements on a catheter device. Thecatheter device intended may be intended for use inside a vasculature orbody duct of a subject that includes inserting the catheter device intothe subject. The catheter device comprising passages for blood flow andmedium flow and inlet and exit ports for blood flow and medium flow. Thecomputer program logic comprising: selecting variables including atleast one of: a) geometrical shapes and dimensions of at least some ofthe blood passages and the medium passages, and b) relative locationsand orientations of flow planes of at least some of the inlet ports andexit ports; and applying a global optimization algorithm to thevariables to generate a catheter with optimized flow conditions. Theglobal optimization algorithm may comprise a genetic algorithm/method.The global optimization algorithm may comprise at least one of simulatedannealing, multistart and interval methods, continuous branch and boundmethods, evolutionary algorithms, and tabu search and scatter searchmethods, as well as other available Global Optimization methods.Furthermore, any other suitable and available approach/algorithm may beimplemented as well.

An aspect of various embodiments of the present invention provides for acatheter device for insertion into a vascular structure or body duct,wherein the catheter device includes a distal end and a proximal end fordelivery of a medium to a lesion. The device comprising: a blood lumenfor allowing blood to pass there through; a medium lumen for thedelivery of a medium to the lesion, the medium lumen comprising at leastone medium egress port for communication with the lesion; an expandablecomponent disposed on the catheter device to block or impede thevascular flow of blood in the vascular structure or body duct; and theblood lumen comprising at least one blood entrance port proximallybefore the expandable component to allow blood to enter and at least oneblood egress port distally beyond the expandable component to allowblood to pass distally beyond the expandable component. The medium mayinclude, for example and not limited thereto, at least one of thefollowing: agent, substance, material, fluid, gas/air, thrombolyticagents, clot lysis agents, chemotherapies, cell slurries, gene therapyvectors, growth factors, contrast agents, angiogenesis factors,radionuclide slurries, anti-infection agents, anti-tumor compounds,receptor-bound agents and/or other types of drugs, therapeutic agentand/or diagnostic agent.

An aspect of various embodiments of the present invention provides amethod for delivering a medium to a lesion inside of a vascularstructure or body duct by inserting a catheter device into a subject.The catheter device may have a distal end and a proximal end, lumensthere through, medium port holes, and blood port holes. The methodcomprises: inflating an expandable component to block or impede thevascular flow of blood or other body fluid through the vasculaturestructure or the body duct; delivering the medium through one of thelumens to the lesion through at least one of the medium port holes; andallowing blood of the vasculature of the subject to proximally enterthrough at least one of the blood port holes and flow through one of thelumens and to exit on a side of the lesion toward the distal end of thecatheter device through at least one of the blood port holes. The mediummay include, for example and not limited thereto, at least one of thefollowing: agent, substance, material, fluid, gas/air, thrombolyticagents, clot lysis agents, chemotherapies, cell slurries, gene therapyvectors, growth factors, contrast agents, angiogenesis factors,radionuclide slurries, anti-infection agents, anti-tumor compounds,receptor-bound agents and/or other types of drugs, therapeutic agentand/or diagnostic agent.

An aspect of various embodiments of the present invention provides acatheterization device that may be designed by use of an adaptivegenetic algorithm computational fluid dynamics approach, as well asother Global Optimization methods that may include simulated annealing,multistart and interval methods, continuous branch and bound methods,evolutionary algorithms, and tabu search and scatter search methods, aswell as other available algorithms/methods that is able to, for example,maximize/optimize the dwell time of an infused agent in the vicinity ofa vascular lesion. The device may have an internal by-pass channel thatallows the blood upstream of the lesion to continue its pulsatile flowthrough the vessel in the part of it occluded by the lesion, whilesimultaneously allowing the disbursement and maximal dwell time of anantithrombolytic or other diagnostic or therapeutic agent needed totreat the lesion. Different embodiments of the catheterization deviceare disclosed and indications for the use of these devices in thetreatment of vascular diseases are discussed.

The invention itself, together with further objects and attendantadvantages, will best be understood by reference to the followingdetailed description taken in conjunction with the accompanyingdrawings.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated into and form a partof the instant specification, illustrate several aspects and embodimentsof the present invention and, together with the description herein,serve to explain the principles of the invention. The drawings areprovided only for the purpose of illustrating select embodiments of theinvention and are not to be construed as limiting the invention.

FIGS. 1 and 2 are cross-sectional side views of the catheter design ofthe present invention located within the lumen of a blood vessel whereblood flow is occluded distal (or partially distal) to the lesion, andshowing blood flow and delivery of an agent through the catheter.

FIGS. 3 and 4 are cross-sectional side views of the catheter design ofthe present invention located within the lumen of a blood vessel whereblood flow is occluded proximal (or partially proximal) to the lesion,and showing blood flow and delivery of an agent through the catheter.

FIG. 5 is a cross-sectional side view of the catheter design of thepresent invention located within the lumen of a blood vessel where bloodflow is occluded around the lesion (or partially around the lesion), andshowing blood flow and delivery of an agent through the catheter.

FIG. 6 schematically illustrates a sectional view VI-VI of an embodimentof the blood flow by-pass catheter provided in FIG. 1.

FIG. 7 schematically illustrates a perspective partial view taken atcross-sectional view VII-VII of the blood flow by-pass catheter providedin FIG. 2.

FIG. 8 is a schematic diagram showing a subject undergoing anexamination and/or intervention inside or in communication with thebore, component or module of an imaging system (or guidance, navigationor tracking system) whereby a catheter device is disposed within thesubject.

FIG. 9 is a functional block diagram for a computer system forimplementation of an exemplary embodiment or portion of an embodiment ofpresent invention.

DETAILED DESCRIPTION OF THE DRAWINGS

Turning now to the drawings, FIG. 1 shows one possible embodiment of ablood flow by-pass catheter 20 for irrigating thrombi or lesions in ablood vessel 10 with medium, such as medication or other diagnostic ortherapeutic agent 16, or other applicable agent, substance, materialmedium or fluid as desired or required. Some examples of medium that maybe transferred from the catheter 20 to the subject may include, but notlimited thereto, the following: agent, substance, material, therapeuticand diagnostic agents, for example, thrombolytic agents, clot lysisagents, chemotherapies, cell slurries, gene therapy vectors, growthfactors, contrast agents, angiogenesis factors, radionuclide slurries,anti-infection agents, anti-tumor compounds, receptor-bound agentsand/or other types of drugs, therapeutic and/or diagnostic agents, andother such substances. The flow of blood 14 is blocked by a temporarilyenlarged portion or expandable component 41 that may be in direct orindirect communication of the outer lumen 26 (or passage) of thecatheter 20 downstream (or at least partially downstream) of thethrombus or lesion 12. This forces the blood 14 through port holes 34 b,for blood entrance, leading through the port hole to the inner lumen 31(or passage), acting as the blood lumen, of the catheter 20 throughwhich it flows until it emerges from port holes 35 b, for blood egress,back into the unobstructed blood vessel 10 downstream of the blockage.The medium 16, such as medication or other diagnostic or therapeuticagent flows through an annular passage, acting as the agent or mediumlumen, in the outer lumen 26 of the catheter 20 and, because the end ofthis passage is sealed at the blockage location, it emerges out of theouter lumen 26 through port holes 25 m, for agent egress, near thethrombus or lesion 12. The presence of the blockage forces the medium ormedication to re-circulate in the vicinity of the thrombus or lesion 12,thus permeating it completely. The rate of irrigation is controlled bythe pressure imposed on the medium or medicated flow and is essentiallyindependent of the blood flow rate. For example, the performance of thecatheter as determined by the flow and species transport through it,shall depend on, among other things, its geometrical and dynamicalcharacteristics. The flow of medium, medication or other diagnostic ortherapeutic agent 16 merges with the flow of blood 14 where it travelsthrough the portholes 34 m and enters the inner lumen 31, acting as theblood lumen, and is discharged with the blood downstream of theblockage.

Still referring to FIG. 1, a microcoil device 51 (or any other suitableimaging/tracking/guiding device or method available), as genericallyshown, may be located at the tip of outer catheter 20 (orspecified/desired location) to help enable a high contrast magneticresonance imaging of the catheter and its environs or a magneticresonance spectroscopy measurement (or any other availableimaging/tracking/guiding methods, procedures, techniques or treatmentsavailable) of species proximal to the tip of catheter 20 in a bloodvessel, body duct, brain or other locations of a patient or subject. Amore detailed discussion of the imaging/tracking/guiding device andmethod will be presented in regard to FIG. 8. A plurality of themicrocoil devices may be used on any combination of overall cathetersystems (for example, see teaching described in commonly assignedInternational Patent Application Serial No.: PCT/US2005/026738, toGillies et al. filed Jul. 28, 2005, entitled “Coaxial Catheter Systemsfor Transference of Medium” and corresponding U.S. application Ser. No.11/191,676, filed Jul. 28, 2005, of which are hereby incorporated byreference herein in their entirety) to best accomplish the magneticresonance imaging or spectroscopy.

It should be appreciated, that as discussed herein a subject may be ahuman or any animal. It should be appreciated that an animal may be avariety of any applicable type, including, but not limited thereto,mammal, veterinarian animal, livestock animal or pet type animal, etc.As an example, the animal may be a laboratory animal specificallyselected to have certain characteristics similar to human (e.g. rat, dogor pig), etc. It should be appreciated that the subject may be anyapplicable patient, for example.

Moreover, it should be appreciated that the various components of thecatheter device 20 as discussed herein may be a variety of commerciallyavailable materials used for all types of catheter systems. Someexamples of materials used for the inner and outer catheters mayinclude, but not limited thereto, the following: polymers, rubber,plastic, composites, metals, ceramics, hydrogels, dialysis membranes andother membranous materials, MR-compatible alloys and materials, andother organic and inorganic compounds and substances and the like. Itshould be appreciated that the various components of the catheter device20, including but not limited thereto, the inner and outer lumens andcomponents thereof, may be flexible or rigid and combination thereof asrequired or desired for intended use. Similarly, the catheter device 20,including but not limited thereto, the inner and outer lumens andcomponents thereof, may provide volume contoured delivery/withdrawal(i.e., transfer) of a medium or blood by adjusting its geometry andflexibility/rigidity according to the target location or anatomy (orregion, including structure and morphology of any lesion) being treated.

FIG. 2 shows another possible embodiment of a blood flow by-passcatheter 20 for irrigating thrombi or lesions in a blood vessel 10 witha medium, such as a medication or other diagnostic or therapeutic agent16, or other applicable medium or fluid as desired or required. The flowof blood 14 is blocked by a temporarily enlarged portion or expandablecomponent 41 that may be in direct or indirect communication of theouter lumen (or passage) 26 of the catheter 20 downstream (or at leastpartially downstream) of the thrombus or lesion 12. This forces theblood 14 through port holes 24 b, for blood entrance, leading to theouter lumen (passage or annulus) 26, acting as the blood lumen, of thecatheter 20 through which it flows until it emerges through port holes25 b, for blood egress, and back into the unobstructed blood vessel 10downstream of the blockage. The medication or other diagnostic ortherapeutic agent 16 flows through the inner lumen (or passage) 31,acting as the agent lumen, of the catheter 20 and, because the end ofthis passage is sealed at the blockage location, it emerges through portholes 35 m, for agent egress, near the thrombus or lesion 12. Thepresence of the blockage forces the medication or other diagnostic ortherapeutic agent 16 to re-circulate in the vicinity of the thrombus orlesion 12, thus permeating it completely. The rate of irrigation iscontrolled by the pressure imposed on the medicated flow and isessentially independent of the blood flow rate. For example, theperformance of the catheter as determined by the flow and speciestransport through it, shall depend on, among other things, itsgeometrical and dynamical characteristics. The flow of medication orother diagnostic or therapeutic agent 16 merges with the flow of blood14 where the blood enters through the portholes 24 into the outer lumen26, acting as the blood lumen, and is discharged with the blooddownstream of the blockage.

FIG. 3 shows a third possible embodiment of a blood flow by-passcatheter 20 for irrigating thrombi or lesions in a blood vessel 10 withmedication or other diagnostic or therapeutic agent 16, or otherapplicable medium or fluid as desired or required. The flow of blood 14is blocked by a temporarily enlarged portion or expandable component 41that may be in direct or indirect communication of the outer lumen 26(or passage) of the catheter 20 upstream (or at least partiallyupstream) of the thrombus or lesion 12. This forces the blood 14 toenter through port holes 34 b, for blood entrance, leading to the innerlumen 31 (or passage), acting as the blood lumen, of the catheter 20through which it flows until it emerges through port holes 35 b, forblood egress, and back into the unobstructed blood vessel 10 downstreamof the blockage. The medium, such as medication or other diagnostic ortherapeutic agent 16, or as desired or required, flows through anannular passage, acting as the agent lumen, in the outer lumen 26 of thecatheter 20 and, because the end of this passage is sealed at theblockage location, it emerges through port holes 25 m, for agent egress,near the thrombus or lesion 12. The presence of the blockage forces themedication or other diagnostic or therapeutic agent 16 to re-circulatein the vicinity of the thrombus or lesion 12, thus permeating itcompletely. The rate of irrigation is controlled by the pressure imposedon the medicated flow and is essentially independent of the blood flowrate. For example, the performance of the catheter as determined by theflow and species transport through it, shall depend on, among otherthings, its geometrical and dynamical characteristics. The flow ofmedication or other diagnostic or therapeutic agent 16 exits from theport holes 35 b and merges with the flow of blood 14 downstream of theblockage and thrombus or lesion 12.

FIG. 4 shows a fourth possible embodiment of a blood flow by-passcatheter 20 for irrigating thrombi or lesion in a blood vessel 10 with amedium, such as medication or other diagnostic or therapeutic agent 16,or other applicable medium or fluid as desired or required. The flow ofblood 14 is blocked by a temporarily enlarged portion or expandablecomponent 41 of the outer lumen of the catheter 20 upstream (or at leastpartially upstream) of the thrombus or lesion 12. This forces the blood14 to enter through port holes 24 b, for blood entrance, leading to theouter lumen passage or annulus) 26, acting as the blood lumen of thecatheter 20 through which it flows until it emerges from port holes 25b, for blood egress, and back into the unobstructed blood vessel 10downstream of the blockage and thrombus or lesion 12. The medication orother diagnostic or therapeutic agent 16 flows through the inner lumen31 (or passage), acting as the agent lumen, of the catheter 20 and,because the end of this passage is sealed just downstream of theblockage location, it emerges through port holes 35 m, for agent egress,near the thrombus or lesion 12. The presence of the blockage forces themedication or other diagnostic or therapeutic agent 16 to re-circulatein the vicinity of the thrombus or lesion 12, thus permeating itcompletely. The rate of irrigation is controlled by the pressure imposedon the medicated flow and is essentially independent of the blood flowrate. For example, the performance of the catheter as determined by theflow and species transport through it, shall depend on, among otherthings, its geometrical and dynamical characteristics. The flow ofmedication or other diagnostic or therapeutic agent 16 merges with theflow of blood 14 downstream of the blockage and thrombus or lesion 12.

FIG. 5 schematically illustrates a fifth possible embodiment of a bloodflow by-pass catheter 20 for irrigating thrombi or lesions in a bloodvessel 10 with a medium, such as medication or other diagnostic ortherapeutic agent 16, or other applicable medium or fluid as desired orrequired. The flow of blood 14 is blocked by a temporarily enlargedportion or expandable component 41 of the outer lumen 26 (or passage) ofthe catheter 20 surrounding (or at least partially surrounding) thethrombus or lesion 12. This forces the blood 14 to enter through portholes 34 b, for blood entrance, leading to the inner lumen 31, acting asthe blood lumen, of the catheter 20 through which it flows until itemerges from port holes 35 b, for blood egress, and back into theunobstructed blood vessel 10 downstream of the blockage. The medicationor other diagnostic or therapeutic agent 16 flows through an annularpassage, acting as the agent lumen, in the outer lumen 26 (or passage)of the catheter 20 and, because the end of this passage is sealed at theblockage location, it emerges through port holes 25 m, of the outerlumen 26 for agent egress, in, through or transverse to the temporarilyenlarged lining or expandable component 22 of the outer lumen 26 thatsurrounds or at least partially surrounds the thrombus or lesion 12. Themedication or other diagnostic or therapeutic agent 16 seeps throughopenings 45 m in this porous lining (or other functional port holes) tobathe the thrombus or lesion 12 and permeates it completely. The rate ofirrigation is controlled by the pressure imposed on the medicated flowand is essentially independent of the blood flow rate. For example, theperformance of the catheter as determined by the flow and speciestransport through it, shall depend on, among other things, itsgeometrical and dynamical characteristics. The flow of medication orother diagnostic or therapeutic agent 16 merges with the flow of blood14 on either side of the thrombus or lesion 12 and is eventually carrieddownstream in the blood vessel 10.

FIG. 6 schematically illustrates a sectional view VI-VI of an embodimentof the blood flow by-pass catheter 20 provided in FIG. 1. The catheter20 contains an outer lumen (passage or annulus) 26 and an inner lumen(passage) 31. Either lumen can be used for the flow of blood or medium(e.g., medication), or inflating the means for blocking the flow ofblood and/or medium.

FIG. 7 schematically illustrates a perspective partial view taken atcross-section VII-VII of the blood flow by-pass catheter 20 provided inFIG. 2. The catheter 20 contains an outer lumen (passage or annulus) 26and an inner lumen (passage) 31. Either lumen can be used for the flowof blood or medium (e.g., medication), or inflating the means forblocking the flow of blood and/or medium. Referring to the partial viewof the embodiment shown in FIG. 2, provided is blood flow by-passcatheter 20 for irrigating thrombi or lesions in a blood vessel 10 witha medium, such as a medication or other diagnostic or therapeutic agent16, or other applicable medium or fluid as desired or required. The flowof blood 14 is blocked by a temporarily enlarged portion or expandablecomponent 41 (not shown) that may be in direct or indirect communicationof the outer lumen (or passage) 26 of the catheter 20 downstream (or atleast partially downstream) of the thrombus or lesion 12. This forcesthe blood 14 through port holes 24 b, for blood entrance, leading to theouter lumen (passage or annulus) 26, acting as the blood lumen, of thecatheter 20 through which it flows until it emerges through port holes25 b, for blood egress, and back into the unobstructed blood vessel 10downstream of the blockage. The medication or other diagnostic ortherapeutic agent 16 flows through the inner lumen (or passage) 31,acting as the agent lumen, of the catheter 20 and, because the end ofthis passage is sealed at the blockage location (not shown), it emergesthrough port holes 35 m, for agent egress, near the thrombus or lesion12. The presence of the blockage forces the medication or otherdiagnostic or therapeutic agent 16 to re-circulate in the vicinity ofthe thrombus or lesion 12, thus permeating it completely. It should beappreciated that angular off set (as designated by the angle referencedas AO) of the inlet passage, via port holes 24 b for blood entrance, andinlet let passage, via port holes 24 m for medium entrance, is along thecircumference of the outer lumen or passage 26. It should further beappreciated that these portholes may be arranged in a variety of ways orlocations along the circumferential and axial (e.g., longitudinal)directions of the lumens.

For the purpose of simplifying the drawings, FIGS. 1-7 may have beenillustrated having various port holes 24 b, 24 m, 34 b, 34 m alignedcircumferentially or axially (e.g., longitudinally) with one another.However, it should be appreciated that the various port holes 24 b, 24m, 34 b, 34 m may be arranged in a variety of locations and wayscircumferentially and axially (e.g., longitudinally) along the innerlumen 31 (inner passage) and outer lumen 26 (outer passage) in supportof the present invention discussed throughout. The dimensions, shapes,contours and angular alignment of the port holes (includingconduit/channel of the portholes) may be varied and designed accordingto the principals and aspects of the present invention.

These particular geometrical configurations of the bypass catheter (asdiscussed in FIGS. 1-7 and through this document) allow for activehydrodynamic control of the medication stream flow (i.e., applicablemedium stream) and of the concentration of medication in it, as well asthe distribution of medication (i.e., applicable medium) in the vicinityof the thrombus, to achieve a specific result. Note that the openings orportholes allowing the flow of blood to bypass the thrombus (or lesion)by entering the inner lumen or passage, and the openings allowing themedication stream to exit the outer lumen or passage, are periodicallyor selectively distributed around (i.e., circumferentially) the catheterin each case. Alternatively, it should be noted that the openings orportholes allowing the flow of blood to bypass the thrombus (or lesion)by entering the outer lumen, and the openings allowing the medicationstream to exit the inner lumen, are periodically or selectivelydistributed around (i.e., circumferentially) the catheter in each case.

As one departure point from various of the existing empirical and/ortrial-and-error designs described in the prior art for such devices,with regards to aspects of various embodiments of the present inventioncatheter devices, systems and related methods we emphasize in whatfollows that these inlet and exit openings can be selectively shaped,staggered and positioned in the circumferential and/or axial (e.g.,longitudinal) directions in order to generate non-intuitive patterns ofplacement that will result in highly three-dimensional, well-mixed flowpatterns in the vicinity of the thrombus or lesion, thus benefiting itsirrigation and maximizing the medication dwell time, such asconcentration and dwell time optimization.

Turning to FIG. 8, FIG. 8 is a schematic diagram showing a patient 110,or any subject or object, undergoing an examination and/or interventioninside or in communication with the bore, component or module of animaging system 112 whereby a catheter device 20 is disposed within thepatient. It should be appreciated that the imaging system 112 may beoperative relative to any part, parts, vasculature, duct, cavity oranatomy of the patient, subject or object as desired or required for theapplicable practice, method, treatment, therapy or procedure. Variousembodiments of the catheter device 20, method of using the catheterdevice, and method of manufacturing the catheter device are capable ofbeing adapted for various purposes and are not limited to use with thefollowing imaging systems 112 including, but not limited thereto, thefollowing: magnetic resonance imaging (MRI) systems, CT systems,radiotherapy systems, fluoroscopy systems, X-ray imaging systems,ultrasound systems, vascular imaging systems, nuclear imaging systems,positron emission tomography, magnetic resonance angiography, andmagnetic resonance spectroscopy systems, and the like. A manifold 114couples several therapeutic or diagnostic devices typified by device 116(or device for any applicable agent, substance, or material) to thedelivery catheter 118. A syringe, flow-driver or pumping device 124 isalso in communication with the manifold 114. The cell delivery catheter118 in turn may be delivered through a guide sheath 120 that may bepositioned in a navigation guide 122. In operation the physician or userinserts the catheter device 118 into the blood vessel (or other anatomypart or duct or subject region) under image system guidance (e.g., MRIguidance or other applicable examination or intervention or imagingsystem discussed herein). The same or similar imaging visualization orMRI visualization may be used to follow the progress of the implant bothacutely and chronically. This specific version of the catheter 20 withinthe concepts disclosed herein may have any of the attributes or relatedmethods of use and manufacture as described herein. The catheter device20, as well as the delivery catheter 118, may have various interior andperipheral ports, lumens and related elements within the context of thedisclosure provided. Such interior and peripheral ports, lumens andrelated elements may be used to deliver other devices and performvarious diagnostic functions. For example, each lumen, port and relatedcatheter element may communicate with a separate port of the manifold114. A lumen, chamber or channel may contain a sensor or transducer 128,such as a pressure transducer, species concentration sensor, fluidmotion stress sensor, or heat sensor, as well as other desired orrequired transducers or sensors. Other lumens and channels may bedevoted to an optical cell counter device, for example. Such a devicemay operate with a plurality of fibers located in one or more separatelumens and/or ports to measure the number of and viability of cells ormedium delivered by the catheter. An example of fiber optics relatedapplication/technology is discussed in U.S. patent application Ser. No.10/444,884, filed May 23, 2003 (U.S. 2003/0204171, published Oct. 30,2003), of which is hereby incorporated by reference herein in itsentirety.

The blood and medication streams flowing through the catheter designs ofinterest, such as those shown in FIGS. 1-8, may be unsteady,three-dimensional and laminar, and to correspond to incompressibleconstant property fluids. The fluid stream passing through the core ofthe catheter is pulsating blood and that passing through the lumen andcontaining the medication is essentially water (saline). Initially, weassume the blood to be a Newtonian fluid since this significantlysimplifies the analysis of the problem. The assumption is valid providedthe shear rates involved are above 1000 s⁻¹ (see: Cokelet G R: TheRheology and Tube Flow of Blood (Chapter 14) in Skalak R, Chien S(eds.): Handbook of Bioengineering. McGraw-Hill, New York, 1987, ofwhich is hereby incorporated by reference herein in its entirety). Forthis condition whole blood with normal hematocrit (about 45%) cangenerally be considered a Newtonian fluid with a viscosity of about 4.2cP at 37° C., about 1.8 times the viscosity of water at the sametemperature (see: Schneck D: Cardiovascular Mechanics, in Enderle J,Blanchard S and Bronzino J, eds., Chapter 10, Introduction to BiomedicalEngineering. Academic Press, New York, 2000, of which is herebyincorporated by reference herein in its entirety). At shear rates belowabout 100 s⁻¹, blood becomes non-Newtonian and viscosity increases asshear rate decreases. The main reasons are reversible cell-cellaggregation and cell deformability. If necessary during thecomputational design process, the Newtonian assumption for blood can berelieved in favor of a more appropriate constitutive relation connectingthe viscous stress to the rate of strain.

To achieve the best-case configurations of the devices shown in FIGS.1-8, for example, computational fluid dynamics is employed within theframework of an adaptive problem-solving methodology based on the use ofGlobal Optimization methods, such as Genetic Algorithms (GAs), thusallowing optimal catheter design(s). Aspects of various embodiments ofthe present invention provide, but not limited thereto, a strategy todynamically accumulate information and use it to improve problem-solvingperformance. To this end, we combine the numerical solution of flow andmass transport conservation equations, for different catheter geometriesand flow conditions, with an adaptive solution methodology based on theuse of Global Optimization methods, such as GAs, to determine optimalcatheter performance. As well as other types of available optimizationalgorithm methods that are available and suitable and appropriate forsuch applications.

Genetic Algorithms (GA) belong to the class of Global Optimizationmethods that include, for example but not limited thereto, simulatedannealing, multistart and interval methods, continuous branch and boundmethods, evolutionary algorithms, and tabu search and scatter searchmethods, as well as other Global Optimization methods not specificallyenumerated herein. A goal of a Global Optimization method is todetermine the absolutely best answer for problems, systems or proceduresthat offer a number of possible solutions. A feature of the GAmethodology is its robustness. Whereas Calculus-based optimization andsearch (hill-climbing) methods lack robustness. Calculus-basedoptimization and search (hill-climbing) methods are local in scope and,once a minimum or maximum is found, require random restarts to initiatesearches for other minima/maxima. Also, calculus-based methods requirethe existence of derivatives whereas many practical problems presentparameter spaces that do not possess well defined slope values. Further,a drawback with regard to enumerative methods is that enumerativemethods systematically search for all solutions of an optimizationproblem in the parameter space, one at a time. However, because anymeaningful problem presents an extremely large number of possiblesolutions in the parameter space it is impracticable to enumerate themall by utilizing the enumerative methods. This lack of efficiencyaccounts for the lack of robustness of enumerative methods. Stillfurther, random search algorithms have been developed to overcome thedeficiencies of calculus-based and enumerative methods but, in the end,random search algorithms also suffer from the lack of efficiencyassociated with enumerative methods. In contrast, the robustness of theGA method, for example, lies in the use of random choice as a tool toguide an extremely exploitative search based on an appropriate coding ofthe relevant parameter space.

The present solution methodology will work in a way similar to aclassical control theory standard feedback loop, wherein a complexprocess (here the performance of a catheter as determined by the flowand species transport through it, which depend on its geometrical anddynamical characteristics) is connected to an adaptive solution strategy(the GA) via a feedback loop. Subject to input data such as catheterdimensions and flow and medication species boundary conditions, theconservation equations yield field solutions for the primary variablesof interest like velocity, pressure and species concentration, and forsecondary quantities derived from the primary like shear stresses andmass fluxes. The primary and secondary quantities allow the evaluationof a preformulated performance measure and part of this numerical outputis the input to the adaptive strategy used to optimize the catheterdesign. The adaptive strategy is responsible for the dynamicalaccumulation of decision-making information through the feedback portionof the loop. It also generates the control actions that modify a currentset of dimensions, variables, or parameters with the expectation thatthe changes will improve the catheter's performance. The description ofthe adaptive solution strategy using GAs provided here follows closelythat given by Queipo N, Devarakonda R and Humphrey J A C: GeneticAlgorithms for Thermosciences Research: Application to the OptimizedCooling of Electronic Components. Int. J. Heat and Mass Transfer37:893-908, 1994, of which is hereby incorporated by reference herein inits entirety.

A GA is an adaptive search procedure loosely based on the Darwiniannotion of evolution by natural selection (see, for instance, Davis L(Editor): Handbook of Genetic Algorithms. Van Nostrand Reinhold, NewYork, 1991, of which is hereby incorporated by reference herein in itsentirety). It uses rules of natural selection to investigate highlycomplex, multidimensional, multivariable problems. GAs have beenemployed in a variety of search, optimization and machine learningapplications in science and engineering where other more traditionalmethods either fail or are subject to significant limitations. Such anapproach has been applied successfully by Humphrey and coworkers (QueipoN, Devarakonda R and Humphrey J A C: Genetic Algorithms forThermosciences Research: Application to the Optimized Cooling ofElectronic Components. Int. J. Heat and Mass Transfer 37:893-908, 1994,of which is hereby incorporated by reference herein in its entirety;Queipo N, Humphrey J A C and Ortega A: Multiobjective Optimal Placementof Convectively Cooled Electronic Components on Printed Wiring Boards.IEEE Transactions on Components, Packaging, and ManufacturingTechnology, Part A 21:142-153, 1988, of which is hereby incorporated byreference herein in its entirety) to find optimal arrangements ofelectronic components, as well as optimal conditions of the flows goingpast them, such that their convective cooling is maximized and none isdestroyed by overheating.

The objects to be optimized geometrically and dynamically here are thedouble lumen bypass catheters depicted in, for example, FIGS. 1-8. Forthis, it is necessary to find the optimal or nearly optimal values of aset of variables and/or their related parameters that minimize a costfunction, and/or maximize a corresponding performance measure, whilesatisfying all imposed problem constraints. For example, the variablescould be, but not limited thereto, the following: a) the geometricalshapes and dimensions of the catheter passages; b) the relativelocations and orientations of the various inlet and exit flow planes; c)the velocity components, pressure, and concentration at specificlocations of blood and/or medium inside and outside the catheter; d) theshear stresses of the flows inside and outside the catheter; and/or e)the concentration and residence time of medication species in thevicinity of the thrombus. Related parameters could be, but not limitedthereto, the Reynolds, Schmidt and/or Pulsating Flow parameters.Constraints could be, but not limited thereto, the following: a) themaximum or minimum allowed sizes of the catheter and of its passagedimensions; b) the maximum allowed flow speeds and/or shear stresses; c)the maximum allowed pressure drop and skin friction; e) the maximumallowed medication concentration; and/or f) the overall expected elapsedtime needed for treatment. The performance measure to be maximized isusually a complicated multidimensional function of quantities like theabove and, often, it is multimodal, possessing several local maxima orminima.

It should be appreciated that an aspect of the various embodiments ofthe present invention is to provide, among other things, a geometricallyand dynamically optimized physical catheter for fabrication andpractical use based on a numerical optimization process. Further, anaspect of the various embodiments of the present invention is toprovide, among other things, the capability to design and test acatheter, and which may be assisted by experimentation. Variousembodiments of the present invention catheter may use solutions of theconservation equations for different geometrical and dynamicalrenditions of the catheter as the data base from which to determine oneor more optimal catheter designs. For this, the GA requires initialinput values associated with an initial set of possible flow andconcentration field solutions to commence the search for an optimalsolution corresponding to one (or more) optimal catheter designs.Through a process based on concepts taken from evolution and using rulesof natural selection, the GA improves upon these solutions. In anycalculation cycle, the set of candidate solutions at time t, P(t),operated upon by the GA is called the population and each member of thisset or generation, when encoded as a string of symbols, is called achromosome. Originally pioneered by Holland (Holland J H: Adaptation inNatural and Artificial Systems. MIT Press, Cambridge, Mass., 1975, ofwhich is hereby incorporated by reference herein in its entirety), a GAmay be abstractly represented by the following sequence of operations:

t=0:

Initialize P(t);

Evaluate P(t);

While (termination condition not satisfied) do

begin

t=t+1;

Select P(t);

Recombine P(t);

Evaluate P(t);

end.

In this representation each iteration in the ‘while’ loop produces a newgeneration of candidate solutions, also encoded as chromosomes. Thus, ifa set of candidate solutions is properly encoded, and the ‘Select’procedure and the GA operators of the ‘Recombine’ procedure areappropriately chosen, each generation of parent solutions will produce ageneration of children solutions (the new set of candidate solutions)which, in general, will have an average performance better than theparent generation. It is the role of the GA operators to construct andpropagate the features of the schema of those chromosomes responsiblefor the improved performance of some candidate solutions relative toothers. The schema reveals the subset of chromosomes possessingsimilarities at certain chromosome positions and the schemata derivedfrom good chromosome solutions within a generation provide the buildingblocks from which to synthesize improved solutions in the offspringgeneration.

For illustration purposes, let us consider a highly simplified example.With reference to the catheter geometry shown in the top schematic ofFIG. 1, call ΔP_(M) the time-averaged pressure drop between the inletand exit locations of the medication stream and call [ω_(M)]_(T) thetime-averaged concentration of the medication species in the vicinity ofthe thrombus. Let us define a cost function or performance measure CFthat rewards increases in [ω_(M)]_(T) and penalizes increases in ΔP_(M).The simplest function is CF=α[ω_(M)]_(T)−βΔP_(M), where α and β areweights given to [ω_(M)]_(T) and ΔP_(M), respectively. Suppose, also, itis found that [ω_(M)]_(T)∝ΔP_(M) so that it is not possible to decreaseΔP_(M) (favorable) without decreasing [ω_(M)]_(T) (unfavorable). Thequestion then is: What catheter geometry will minimize ΔP_(M) whilemaximizing [ω_(M)]_(T) in order to maximize CF?

Let us further assume, also for illustration purposes, we find that thethree most critical geometrical parameters bearing on the maximizationof CF are the inner diameter D_(b) of the passage through which theblood flows, the annulus gap size D_(m) of the passage through which themedication stream (or applicable medium) flows, and the distance L_(i-e)between the inlet and exit planes for the medication stream. Forexample, the distance L_(i-e) would be due to the angular off set thatthe inlet passage and out let passage is along the circumference of thelumen(s). If we encode these quantities in microns using a 13 unitbinary numbering scheme, then any of them can, in principle, rangebetween 0000000000000 and 1111111111111 or, equivalently, between 0 and8191 μm. Suppose we find via numerical calculation of the flow andmedication species fields that the largest value of CF corresponds toD_(b)=500 μm, D_(m)=250 μm and L_(i-e)=8000 μm. Then theD_(b)-D_(m)-L_(i-e) chromosome corresponding to this geometry is givenby 0010111110000-0101111100000-0000001011111. Generally, it is expectedthat the flow and mass transport characteristics of the optimal cathetergeometry represented by this chromosome will differ from other lessoptimal (or unacceptable) geometries given by chromosomes such as, forexample, 001011 0110000-0101111100000-0000 101011111 and 0000111110001-0101100100000-0000 01111101. Note, however, that by exchangingthe highlighted units in the first and third genes of these twochromosomes the original optimal chromosome results.

Thus, it is an objective of the adaptive search strategy, based on theuse of the GA, to find the chromosome(s) corresponding to the optimalcatheter(s) from among a very large number of alternative possibilitiesevolving under imposed natural selection rules. For example, assuminginteger increments of ±1 μm, the number of distinct chromosomes based onthe three-gene D_(b)-D_(a)-L_(i-e) sequence above is alreadyN=500×250×8000=109. Further, it should be appreciated that the inclusionof additional genes (representing other important geometrical ordynamical features) in the chromosome makes the number of potentiallypossible solutions even larger. Notwithstanding, the power of the GAapproach resides in its ability to home in on optimal or near optimalchromosomes (representing optimal catheter designs) within a fewgenerations.

In a typical GA, the initial set of candidate solutions or encodedchromosomes (in the present case, the geometrical and dynamicalcharacteristics of a catheter) is usually selected randomly. However,preliminary calculations (or experimental results) can help narrow downthe range of values. There appear to be no definitive rules regardingthe best initial solution population size for a given problem butguidelines are given in Grefenstette J J: Optimization of ControlParameters for Genetic Algorithms. IEEE Trans. Systems, Man CyberneticsSMC-16 (1):122-128, 1986, of which is hereby incorporated by referenceherein in its entirety. The candidate solutions are encoded asfixed-length chromosomes for which different encoding schemes, such asbinary (as illustrated above) and integer, have been used.

In the GA operation sequence defined above, the ‘Evaluate’ procedurecalculates the fitness of each chromosome; this is the measure ofperformance associated with each candidate solution. It is an importantquantity since the probability that a chromosome in the parentpopulation will contribute its schema to the offspring generation isproportional to the chromosome's relative fitness. The function of the‘Select’ procedure is to specify the actual number of offspring thateach parent chromosome contributes to the next generation based on therelative performance of that chromosome. Different selection mechanismsare discussed in Baker J E: Reducing bias and efficiency in theselection algorithm. Proceedings of the Second International Conferenceon Genetic Algorithms, pp. 14-21. Lawrence Erlbaum, Hillsdale, N.J.,1987, of which is hereby incorporated by reference herein in itsentirety. The ‘Recombine’ procedure contains the GA operators that areexpected to construct and propagate the schema responsible for goodperformance. The most prominent GA ‘Recombine’ operators are crossoverand mutation. The crossover operator acts on two chromosomes at a time,on average generating fitter offspring by combining the schema in eachparent. The mutation operator usually involves the infrequent randomalteration of the value of one or more bits in a chromosome. Crossoverand mutation operators for binary chromosomes and, because they can alsodisrupt desirable schema, it is important to specify them appropriatelyin the GA. In a GA application, the Select, Recombine and Evaluateprocedures are repeated from generation to generation until somepre-established convergence or termination criterion is satisfied.

Turning to FIG. 9, FIG. 9 is a functional block diagram for a computersystem 900 for implementation of an exemplary embodiment or portion ofan embodiment of present invention. For example, a method of anembodiment of the present invention may be implemented using hardware,software or a combination thereof and may be implemented in one or morecomputer systems or other processing systems, such as personal digitassistants (PDAs), operated to achieve the best-case or optimizedconfigurations of the catheter devices shown in FIGS. 1-8 and discussedthroughout. For example, the processing of computational fluid dynamicsmay be employed within the framework of an adaptive problem-solvingmethodology that is based on the use of present invention GlobalOptimization methods and techniques, such as Genetic Algorithms (GAs)that allow for optimal or best-case catheter device design(s).

In an example embodiment, an embodiment of the invention was implementedin software running on a general purpose computer 900 as illustrated inFIG. 9. Computer system 900 includes one or more processors, such asprocessor 904 Processor 904 is connected to a communicationinfrastructure 906 (e.g., a communications bus, cross-over bar, ornetwork). Computer system 900 may include a display interface 902 thatforwards graphics, text, and other data from the communicationinfrastructure 906 (or from a frame buffer not shown) for display on thedisplay unit 930.

Computer system 900 also includes a main memory 908, preferably randomaccess memory (RAM), and may also include a secondary memory 910. Thesecondary memory 910 may include, for example, a hard disk drive 912and/or a removable storage drive 914, representing a floppy disk drive,a magnetic tape drive, an optical disk drive, a flash memory, etc. Theremovable storage drive 914 reads from and/or writes to a removablestorage unit 918 in a well known manner. Removable storage unit 918,represents a floppy disk, magnetic tape, optical disk, etc. which isread by and written to by removable storage drive 914. As will beappreciated, the removable storage unit 918 includes a computer usablestorage medium having stored therein computer software and/or data.

In alternative embodiments, secondary memory 910 may include other meansfor allowing computer programs or other instructions to be loaded intocomputer system 900. Such means may include, for example, a removablestorage unit 922 and an interface 920. Examples of such removablestorage units/interfaces include a program cartridge and cartridgeinterface (such as that found in video game devices), a removable memorychip (such as a ROM, PROM, EPROM or EEPROM) and associated socket, andother removable storage units 922 and interfaces 920 which allowsoftware and data to be transferred from the removable storage unit 922to computer system 900.

Computer system 900 may also include a communications interface 924.Communications interface 924 allows software and data to be transferredbetween computer system 900 and external devices. Examples ofcommunications interface 924 may include a modem, a network interface(such as an Ethernet card), a communications port (e.g., serial orparallel, etc.), a PCMCIA slot and card, a modem, etc. Software and datatransferred via communications interface 924 are in the form of signals928 which may be electronic, electromagnetic, optical or other signalscapable of being received by communications interface 924. Signals 928are provided to communications interface 924 via a communications path(i.e., channel) 926. Channel 926 carries signals 928 and may beimplemented using wire or cable, fiber optics, a phone line, a cellularphone link, an RF link, an infrared link, wireless link or connectionand other communications channels.

In this document, the terms “computer program medium” and “computerusable medium” are used to generally refer to media such as removablestorage drive 914, a hard disk installed in hard disk drive 912, andsignals 928. These computer program products are means for providingsoftware to computer system 900. The invention includes such computerprogram products.

Computer programs (also called computer control logic) are stored inmain memory 908 and/or secondary memory 910. Computer programs may alsobe received via communications interface 924. Such computer programs,when executed, enable computer system 900 to perform the features of thepresent invention as discussed herein. In particular, the computerprograms, when executed, enable processor 904 to perform the functionsof the present invention. Accordingly, such computer programs representcontrollers of computer system 900.

In an embodiment where the invention is implemented using software, thesoftware may be stored in a computer program product and loaded intocomputer system 900 using removable storage drive 914, hard drive 912 orcommunications interface 924. The control logic (software), whenexecuted by the processor 904, causes the processor 904 to perform thefunctions of the invention as described herein.

In another embodiment, the invention is implemented primarily inhardware using, for example, hardware components such as applicationspecific integrated circuits (ASICs). Implementation of the hardwarestate machine to perform the functions described herein will be apparentto persons skilled in the relevant art(s).

In yet another embodiment, the invention is implemented using acombination of both hardware and software.

In an example software embodiment of the invention, the methodsdescribed above were implemented in SPSS control language, but could beimplemented in other programs such as, but not limited to, C++programming language or other programs available to those skilled in theart.

The devices, methods and computer program product of various embodimentsof the present invention discussed throughout may be practiced andimplemented with the methods, systems and devices disclosed in thefollowing U.S. patents and U.S. patent application Publications, and ofwhich are hereby incorporated by reference herein in their entirety:

U.S. Pat. No. 6,840,949 to Barbut, entitled “Devices and Methods forPreventing Distal Embolization Using Flow Reversal in Arteries HavingCollateral Blood Flow;”

U.S. Pat. No. 6,830,579 to Barbut, entitled “Devices and Methods forPreventing Distal Embolization Using Flow Reversal and PerfusionAugmentation Within the Cerebral Vasculature;”

U.S. Pat. No. 6,830,577 to Nash et al., entitled “System and Method ofUse for Treating Occluded Vessels and Diseased Tissue;”

U.S. Pat. No. 6,796,992, to Barbut, entitled “Cerebral PerfusionAugmentation;”

U.S. Pat. No. 6,790,204 to Zadno-Azizi et al., entitled Method forContaining and Removing Occlusions in the Carotid Arteries;”

U.S. Pat. No. 6,767,345, to St. Germain et al., entitled “Partial AorticOcclusion Devices and Methods for Renal and Coronary PerfusionAugmentation;”

U.S. Pat. No. 6,755,846, to Yadav, entitled “Vascular Filter;”

U.S. Pat. No. 6,743,208 to Coyle, entitled “Occlusion Balloon Catheterwith Distal Valve;”

U.S. Pat. No. 6,743,196 to Barbut et al., entitled “Partial AorticOcclusion Devices and Methods for Cerebral Perfusion Augmentation;”

U.S. Pat. No. 6,733,474 to Kusleika, entitled “Catheter for TissueDilatation and Drug Delivery;”

U.S. Pat. No. 6,730,063 to Delaney et al., entitled “Catheter Devicesand Methods for Their Use in the Treatment of Calcified VascularOcclusions;”

U.S. Pat. No. 6,712,806 to St. Germain et al., entitled “Partial AorticOcclusion Devices and Methods for Cerebral Perfusion Augmentation;”

U.S. Pat. No. 6,712,798 to Constantz, entitled “Multilumen Catheters andMethods for Their Use;”

U.S. Pat. No. 6,660,021 to Palmer et al., entitled “Intravascular Deviceand System;”

U.S. Pat. No. 6,635,046 to Barbut, entitled “Partial Aortic OcclusionDevices and Methods for Cerebral Perfusion Augmentation;”

U.S. Pat. No. 6,613,076 to Cherif-Cheikh, entitled “ImplantableIntraluminal Device;”

U.S. Pat. No. 6,592,557 to Barbut, entitled “Partial Aortic OcclusionDevices and Methods for Cerebral Perfusion Augmentation;”

U.S. Pat. No. 6,582,448 to Boyle et al., entitled “Vessel OcclusionDevice for Embolic Protection System;”

U.S. Pat. No. 6,565,552 to Barbut, entitled “Partial Aortic OcclusionDevices and Methods for Cerebral Perfusion Augmentation;”

U.S. Pat. No. 6,558,401 to Azizi, entitled “Low Profile Catheter forAngioplasty and Occlusion;”

U.S. Pat. No. 6,558,356 to Barbut, entitled “Medical Device for FlowAugmentation in Patients With Occlusive Cerebrovascular Disease andMethods of Use;” U.S. Pat. No. 6,533,800 to Barbut, entitled “Devicesand Methods for Preventing Distal Embolization Using Flow Reversal inArteries Having Collateral Blood Flow;”

U.S. Pat. No. 6,533,767 to Johansson et al., entitled “Methods forEnhancing Fluid Flow Through an Obstructed Vascular Site;”

U.S. Pat. No. 6,506,180 to Lary, entitled “Passive PerfusionSleeve/Placement Catheter Assembly;”

U.S. Pat. No. 5,792,105 to Lin et al., entitled Multichannel BalloonCatheter for Delivering Fluid;”

U.S. Pat. No. 5,254,089 to Wang, entitled “Medication Dispensing BalloonCatheter;”

U.S. Pat. No. 5,021,044 to Sharkawy, entitled “Catheter for EvenDistribution of Therapeutic Fluids;” and

U.S. Pat. Application Publication No. 2004/0162519 A1 to Helkowski etal., entitled Aortic Occlusion Balloon Cannula.”

One skilled in the art can see that many other embodiments of the lumensand number of lumens, annular passages, means for flow-blockage, flowchanneling and recirculation, and other details of construction and useconstitute non-inventive variations of the novel and insightfulconceptual means, system and technique which underlie the presentinvention.

Still other embodiments will become readily apparent to those skilled inthis art from reading the above-recited detailed description anddrawings of certain exemplary embodiments. It should be understood thatnumerous variations, modifications, and additional embodiments arepossible, and accordingly, all such variations, modifications, andembodiments are to be regarded as being within the spirit and scope ofthis application. For example, regardless of the content of any portion(e.g., title, field, background, summary, abstract, drawing figure,etc.) of this application, unless clearly specified to the contrary,there is no requirement for the inclusion in any claim herein or of anyapplication claiming priority hereto of any particular described orillustrated activity or element, any particular sequence of suchactivities, or any particular interrelationship of such elements.Moreover, any activity can be repeated, any activity can be performed bymultiple entities, and/or any element can be duplicated. Further, anyactivity or element can be excluded, the sequence of activities canvary, and/or the interrelationship of elements can vary. Unless clearlyspecified to the contrary, there is no requirement for any particulardescribed or illustrated activity or element, any particular sequence orsuch activities, any particular size, speed, material, dimension orfrequency, or any particularly interrelationship of such elements.Accordingly, the descriptions and drawings are to be regarded asillustrative in nature, and not as restrictive. Moreover, when anynumber or range is described herein, unless clearly stated otherwise,that number or range is approximate. When any range is described herein,unless clearly stated otherwise, that range includes all values thereinand all sub ranges therein. Any information in any material (e.g., aUnited States/foreign patent, United States/foreign patent application,book, article, etc.) that has been incorporated by reference herein, isonly incorporated by reference to the extent that no conflict existsbetween such information and the other statements and drawings set forthherein. In the event of such conflict, including a conflict that wouldrender invalid any claim herein or seeking priority hereto, then anysuch conflicting information in such incorporated by reference materialis specifically not incorporated by reference herein.

1. A catheter device for insertion into a vascular structure or bodyduct, wherein said catheter device designed by employment of a globaloptimization algorithm based computational fluid dynamics approach,wherein said catheter device having a distal end and a proximal end fordelivery of a medium to a lesion, said device comprising: a blood lumenfor allowing blood to pass there through; a medium lumen for thedelivery of a medium to the lesion, said medium lumen comprising atleast one medium egress port for communication with the lesion; anexpandable component disposed on said catheter device to block or impedethe vascular flow of blood in the vascular structure or body duct; andsaid blood lumen comprising at least one blood entrance port proximallybefore said expandable component to allow blood to enter and at leastone blood egress port distally beyond said expandable component to allowblood to pass distally beyond said expandable component.
 2. The deviceof claim 1, wherein the medium comprises at least one of agent,substance, material, thrombolytic agents, clot lysis agents,chemotherapies, cell slurries, gene therapy vectors, growth factors,contrast agents, angiogenesis factors, radionuclide slurries,anti-infection agents, anti-tumor compounds, receptor-bound agentsand/or other types of drugs, therapeutic agent and/or diagnostic agent.3. The device of claim 1, wherein: said expandable component comprisesat least one port, said at least one port of said expandable componentbeing in communication with said at least one medium egress port forcommunication of the medium with the lesion.
 4. The device of claim 3,wherein a plurality of said at least one port of said expandablecomponent comprises a porous surface of said expandable component. 5.The device of claim 1, wherein said expandable component is at least oneof inflatable balloon, angioplasty balloon means, an occlusive stent, amechanically or otherwise expandable sleeve, a chemically or otherwiseactivated foam-based occluder, an electrically or magnetically activatedocclusion means, or any combination of said such occlusive devices,means and methods.
 6. The device of claim 5, wherein said angioplastyballoon is inflated by fluid provided through a delivery lumen of saidcatheter.
 7. The device of claim 1, wherein said expandable componentbeing actuated by at least one of the following processes:hydraulically, pneumatically, electrically, magnetically, chemically orby some other physical process.
 8. The device of claim 1, wherein saidexpandable component is a temporarily enlargeable lining of outer wallof said catheter device.
 9. The device of claim 8, wherein saidenlargement being actuated by at least one of the following processes:hydraulically, pneumatically, electrically, magnetically, chemically orby some other physical process.
 10. The device of claim 1, furthercomprising a means for pumping said medium through said medium lumen.11. The device of claim 10, wherein said pumping means comprises atleast one of syringe, flow-driver, or pumping device.
 12. The device ofclaim 1, further comprising a plurality of micro-coils disposed near orat the distal tip of said catheter, said micro-coils for improvedmagnetic resonance imaging and/or magnetic resonance spectroscopy. 13.The device of claim 1, wherein said global optimization algorithmcomprises a genetic algorithm.
 14. The device of claim 1, wherein saidglobal optimization algorithm comprises at least one of simulatedannealing, multistart and interval methods, continuous branch and boundmethods, evolutionary algorithms, and tabu search and scatter searchmethods, as well as other available Global Optimization methods.
 15. Amethod for delivering a medium to a lesion inside of a vascularstructure or body duct by inserting a catheter device designed by aglobal optimization algorithm based computational fluid dynamicsapproach into a subject, said catheter device having a distal end and aproximal end, lumens there through, medium port holes, and blood portholes, wherein said method comprises: inflating an expandable componentto block or impede the vascular flow of blood or other body fluidthrough the vasculature structure or the body duct; delivering themedium through one of said lumens to said lesion through at least one ofsaid medium port holes; and allowing blood of the vasculature of thesubject to proximally enter through at least one of said blood portholes and flow through one of said lumens and to exit on a side of saidlesion toward said distal end of said catheter device through at leastone of said blood port holes.
 16. The method of claim 15, wherein themedium comprises at least one of agent, substance, material,thrombolytic agents, clot lysis agents, chemotherapies, cell slurries,gene therapy vectors, growth factors, contrast agents, angiogenesisfactors, radionuclide slurries, anti-infection agents, anti-tumorcompounds, receptor-bound agents and/or other types of drugs,therapeutic agent and/or diagnostic agent.
 17. The method of claim 15,wherein said inflating comprises placing said expandable component on aside of said lesion that is toward said distal end of said catheterdevice or placing a portion of said expandable component on a side ofsaid lesion that is toward said distal end of said catheter device. 18.The method of claim 15, wherein said inflating comprises placing saidexpandable component on a side of said lesion that is toward saidproximal end of said catheter device or placing a portion of saidexpandable component on a side of said lesion that is toward saidproximal end of said catheter device.
 19. The method of claim 15,wherein said inflating comprises placing said expandable component tosurround said lesion or at least partially surround said lesion.
 20. Themethod of claim 15, wherein said inflating comprises placing saidexpandable component adjacent to said lesion or at least partiallyadjacent to said lesion.
 21. The method of claim 15, wherein saiddelivering the medium comprises sending the medium through said mediumport holes that are: located on a side of said expandable component thatis toward said distal end of said catheter device, or partially locatedon a side of said expandable component that is toward said distal end ofsaid catheter device.
 22. The method of claim 15, wherein saiddelivering comprises: sending said medium through said medium port holesthat are located on a side of said expandable component that is towardsaid proximal end of said catheter device, or partially located on aside of said expandable component that is toward said proximal end ofsaid catheter device; and re-entering said medium through said mediumport holes.
 23. The method of claim 15, wherein: said expandablecomponent comprises a at least one port hole disposed thereto or incommunication therewith; and said delivering comprises sending saidmedium through said expandable component.
 24. The method of claim 15,further comprising performing an angioplasty procedure on said lesionusing said expandable component.
 25. The method of claim 15, furthercomprising controlling the rate of irrigation of said medium with saidlesion.
 26. The method of claim 15, wherein said global optimizationalgorithm comprises a genetic algorithm.
 27. The method of claim 15,wherein said global optimization algorithm comprises at least one ofsimulated annealing, multistart and interval methods, continuous branchand bound methods, evolutionary algorithms, and tabu search and scattersearch methods, as well as other available Global Optimization methods.28. A method for generating a configuration of elements of a catheterdevice for use inside a vasculature or body duct of a subject thatincludes inserting said catheter device into the subject, said catheterdevice comprising passages for blood flow and medium flow and inlet andexit ports for blood flow and medium flow, said method comprising:selecting variables including at least one of: a) geometrical shapes anddimensions of at least some of said blood passages and said mediumpassages, and b) relative locations and orientations of flow planes ofat least some of said inlet ports and exit ports; and applying a globaloptimization algorithm to the variables to generate a catheter withoptimized flow conditions.
 29. The method of claim 28, wherein saidvariables further comprise: velocity components, vorticity components,pressure, and/or concentration of blood and/or medium at specificlocations of blood and/or medium inside and outside of the catheterdevice.
 30. The method of claim 28, wherein said variables furthercomprise at least one of: a) shear stresses and/or vorticity componentsof the flow of the blood and/or medium inside and outside said catheterdevice; and b) concentration and residence time of medium in thevicinity of the specific location outside said catheter device.
 31. Themethod of claim 30, wherein the specific location outside said catheterdevice being located in the vasculature or tubular body duct.
 32. Themethod of claim 30, wherein said variables further comprise at least oneof: Reynolds, Schmidt and/or Pulsating Flow parameters for the bloodand/or medium.
 33. The method of claim 30, wherein said method furthercomprises applying constraints to said generation comprising at leastone of: a) maximum or minimum allowed sizes of the catheter and/ordimensions said passages; b) maximum allowed flow speeds and/or shearstresses; c) maximum allowed pressure drop and skin friction; e) maximumallowed medication concentration; and f) overall expected elapsed timeneeded for treatment.
 34. The method of any one of claims 28, 29, 30, 32and 33, wherein said global optimization algorithm comprises a geneticalgorithm.
 35. The method of any one of claims 28, 29, 30, 32 and 33,wherein said global optimization algorithm comprises at least one ofsimulated annealing, multistart and interval methods, continuous branchand bound methods, evolutionary algorithms, and tabu search and scattersearch methods, as well as other available Global Optimization methods.36. The method of claim 28, wherein the medium comprises at least one ofagent, substance, material, thrombolytic agents, clot lysis agents,chemotherapies, cell slurries, gene therapy vectors, growth factors,contrast agents, angiogenesis factors, radionuclide slurries,anti-infection agents, anti-tumor compounds, receptor-bound agentsand/or other types of drugs, therapeutic agent and/or diagnostic agent.37. A computer program product comprising a computer useable mediumhaving computer program logic for enabling at least one processor in acomputer system to generate a configuration of elements on a catheterdevice, wherein said catheter device intended for use inside avasculature or body duct of a subject that includes inserting saidcatheter device into the subject, said catheter device comprisingpassages for blood flow and medium flow and inlet and exit ports forblood flow and medium flow, said computer program logic comprising:selecting variables including at least one of: a) geometrical shapes anddimensions of at least some of said blood passages and said mediumpassages, and b) relative locations and orientations of flow planes ofat least some of said inlet ports and exit ports; and applying a globaloptimization algorithm to the variables to generate a catheter withoptimized flow conditions.
 38. The computer program product of claim 37,wherein said variables further comprise: velocity components, vorticitycomponents, pressure, and/or concentration of blood and/or medium atspecific locations of blood and/or medium inside and outside of thecatheter device.
 39. The computer program product of claim 37, whereinsaid variables further comprise at least one of: a) shear stressesand/or vorticity components of the flow of the blood and/or mediuminside and outside said catheter device; and b) concentration andresidence time of medium in the vicinity of the specific locationoutside said catheter device.
 40. The computer program product of claim39, wherein the specific location outside said catheter device beinglocated in the vasculature or tubular body duct.
 41. The computerprogram product of claim 39, wherein said variables further comprise atleast one of: Reynolds, Schmidt and/or Pulsating Flow parameters for theblood and/or medium.
 42. The computer program product of claim 39,wherein said method further comprises applying constraints to saidgeneration comprising at least one of: a) maximum or minimum allowedsizes of the catheter and/or dimensions of said passages; b) maximumallowed flow speeds and/or shear stresses; c) maximum allowed pressuredrop and skin friction, e) maximum allowed medication concentration; andf) overall expected elapsed time needed for treatment.
 43. The computerprogram product of any one of claims 37, 38, 39, 41 and 42, wherein saidglobal optimization algorithm comprises a genetic algorithm.
 44. Thecomputer program product of any one of claims 37, 38, 39, 41 and 42,wherein said global optimization algorithm comprises at least one ofsimulated annealing, multistart and interval methods, continuous branchand bound methods, evolutionary algorithms, and tabu search and scattersearch methods, as well as other available Global Optimization methods.45. A catheter device for insertion into a vascular structure or bodyduct, wherein said catheter device having a distal end and a proximalend for delivery of a medium to a lesion, said device comprising: ablood lumen for allowing blood to pass there through; a medium lumen forthe delivery of a medium to the lesion, said medium lumen comprising atleast one medium egress port for communication with the lesion; anexpandable component disposed on said catheter device to block or impedethe vascular flow of blood in the vascular structure or body duct; andsaid blood lumen comprising at least one blood entrance port proximallybefore said expandable component to allow blood to enter and at leastone blood egress port distally beyond said expandable component to allowblood to pass distally beyond said expandable component.
 46. The deviceof claim 45, wherein the medium comprises at least one of agent,substance, material, thrombolytic agents, clot lysis agents,chemotherapies, cell slurries, gene therapy vectors, growth factors,contrast agents, angiogenesis factors, radionuclide slurries,anti-infection agents, anti-tumor compounds, receptor-bound agentsand/or other types of drugs, therapeutic agent and/or diagnostic agent.47. The device of claim 45, wherein: said expandable component comprisesat least one port, said at least one port of said expandable componentbeing in communication with said at least one medium egress port forcommunication of the medium with the lesion.
 48. The device of claim 47,wherein a plurality of said at least one port of said expandablecomponent comprises a porous surface of said expandable component. 49.The device of claim 45, wherein said expandable component is at leastone of inflatable balloon, angioplasty balloon means, an occlusivestent, a mechanically or otherwise expandable sleeve, a chemically orotherwise activated foam-based occluder, an electrically or magneticallyactivated occlusion means, or any combination of said such occlusivedevices, means and methods.
 50. The device of claim 49, wherein saidangioplasty balloon is inflated by fluid provided through a deliverylumen of said catheter.
 51. The device of claim 45, wherein saidexpandable component being actuated by at least one of the followingprocesses: hydraulically, pneumatically, electrically, magnetically,chemically or by some other physical process.
 52. The device of claim45, wherein said expandable component is a temporarily enlargeablelining of outer wall of said catheter device.
 53. The device of claim52, wherein said enlargement being actuated by at least one of thefollowing processes: hydraulically, pneumatically, electrically,magnetically, chemically or by some other physical process.
 54. Thedevice of claim 45, further comprising a means for pumping said mediumthrough said medium lumen.
 55. The device of claim 54, wherein saidpumping means comprises at least one of syringe, flow-driver, or pumpingdevice.
 56. The device of claim 45, further comprising a plurality ofmicro-coils disposed near or at the distal tip of said catheter, saidmicro-coils for improved magnetic resonance imaging and/or magneticresonance spectroscopy.
 57. A method for delivering a medium to a lesioninside of a vascular structure or body duct by inserting a catheterdevice into a subject, said catheter device having a distal end and aproximal end, lumens there through, medium port holes, and blood portholes, wherein said method comprises: inflating an expandable componentto block or impede the vascular flow of blood or other body fluidthrough the vasculature structure or the body duct; delivering themedium through one of said lumens to said lesion through at least one ofsaid medium port holes; and allowing blood of the vasculature of thesubject to proximally enter through at least one of said blood portholes and flow through one of said lumens and to exit on a side of saidlesion toward said distal end of said catheter device through at leastone of said blood port holes.
 58. The method of claim 57, wherein themedium comprises at least one of agent, substance, material,thrombolytic agents, clot lysis agents, chemotherapies, cell slurries,gene therapy vectors, growth factors, contrast agents, angiogenesisfactors, radionuclide slurries, anti-infection agents, anti-tumorcompounds, receptor-bound agents and/or other types of drugs,therapeutic agent and/or diagnostic agent.
 59. The method of claim 57,wherein said inflating comprises placing said expandable component on aside of said lesion that is toward said distal end of said catheterdevice or placing a portion of said expandable component on a side ofsaid lesion that is toward said distal end of said catheter device. 60.The method of claim 57, wherein said inflating comprises placing saidexpandable component on a side of said lesion that is toward saidproximal end of said catheter device or placing a portion of saidexpandable component on a side of said lesion that is toward saidproximal end of said catheter device.
 61. The method of claim 57,wherein said inflating comprises placing said expandable component tosurround said lesion or at least partially surround said lesion.
 62. Themethod of claim 57, wherein said inflating comprises placing saidexpandable component adjacent to said lesion or at least partiallyadjacent to said lesion.
 63. The method of claim 57, wherein saiddelivering the medium comprises sending the medium through said mediumport holes that are: located on a side of said expandable component thatis toward said distal end of said catheter device, or partially locatedon a side of said expandable component that is toward said distal end ofsaid catheter device.
 64. The method of claim 57, wherein saiddelivering comprises: sending said medium through said medium port holesthat are located on a side of said expandable component that is towardsaid proximal end of said catheter device, or partially located on aside of said expandable component that is toward said proximal end ofsaid catheter device; and re-entering said medium through said mediumport holes.
 65. The method of claim 57, wherein: said. expandablecomponent comprises a at least one port hole disposed thereto or incommunication therewith; and said delivering comprises sending saidmedium through said expandable component.
 66. The method of claim 57,further comprising performing an angioplasty procedure on said lesionusing said expandable component.
 67. The method of claim 57, furthercomprising controlling the rate of irrigation of said medium with saidlesion.